Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Synapse (New York, N.Y.)|June 1, 1994
No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeysR J Vermeulen, B Drukarch, N P Verhoeff, et al.
British Journal of Clinical Pharmacology|June 9, 2007
Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomesVincent C Peterkin, Jonathan N Bauman, Theunis C Goosen, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2014
Undesired versus designed enzymatic cleavage of linkers for liver targetingSrinivas R Chirapu, Jonathan N Bauman, Heather Eng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 2022
Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting ApproachAngela C Doran, Woodrow Burchett, Connor Landers, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 4, 2017
Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic ActivityBrahim Achour, Alyssa Dantonio, Mark Niosi, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 22, 2013
Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyondHugh A Barton, Yurong Lai, Theunis C Goosen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 28, 2005
Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomesJonathan N Bauman, Theunis C Goosen, Meera Tugnait, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 12, 2004
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratiosJ Andrew Williams, Ruth Hyland, Barry C Jones, et al.
Molecular Pharmaceutics|June 30, 2011
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1Manthena V Varma, Charles J Rotter, Jonathan Chupka, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012
Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.
Pageof 9